Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.5.2349

P53 Arg72Pro Polymorphism and Bladder Cancer Risk - Meta-analysis Evidence for a Link in Asians but not Caucasians  

Xu, Ting (Department of Urologic Surgery, The Affiliated Cancer Hospital of Jiangsu Province, Nanjing Medical University)
Xu, Zi-Cheng (Department of Urologic Surgery, The Affiliated Cancer Hospital of Jiangsu Province, Nanjing Medical University)
Zou, Qin (Department of Urologic Surgery, The Affiliated Cancer Hospital of Jiangsu Province, Nanjing Medical University)
Yu, Bin (Department of Urologic Surgery, The Affiliated Cancer Hospital of Jiangsu Province, Nanjing Medical University)
Huang, Xin-En (Department of Chemotherapy, the Affiliated Cancer Hospital of Jiangsu Province, Nanjing Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.5, 2012 , pp. 2349-2354 More about this Journal
Abstract
Objective: Individual studies of the associations between P53 codon 72 polymorphism (rs1042522) and bladder cancer susceptibility have shown inconclusive results. To derive a more precise estimation of the relationship, we performed this systemic review and meta-analysis based on 15 publications. Methods: We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. Results: We found that there was no association between P53 codon 72 polymorphism and bladder cancer risk in the comparisons of Pro/Pro vs Arg/Arg; Pro/Arg vs. Arg/Arg; Pro/Pro plus Pro/Arg vs. Arg/Arg; Arg/Arg vs. Pro/Arg plus Arg/Arg (OR=1.06 95%CI 0.81-1.39; OR=1.06 95%CI 0.83-1.36; OR=0.98 95%CI 0.78-1.23; OR=1.06 95%CI 0.84-1.32). However, a significantly increased risk of bladder cancer was found among Asians in the homozygote comparison (Pro/Pro vs. Arg/Arg, OR=1.36 95%CI 1.05-1.75, P=0.790 for heterogeneity) and the dominant model (Arg/Pro plus Pro/Pro vs. Arg/Arg, OR=1.26 95%CI 1.05-1.52, P=0.564 for heterogeneity). In contrast, no evidence of an association between bladder cancer risk and P53 genotype was observed among Caucasian population in any genetic model. When stratifying for the stage of bladder, no statistical association were found (Pro/Pro vs. Arg/Arg, OR=0.45 95%CI 0.17-1.21; Pro/Arg vs. Arg/Arg, OR=0.60 95%CI 0.28-1.27; Dominant model, OR=0.56 95%CI 0.26-1.20; Recessive model, OR=0.62 95%CI0.35-1.08) between P53 codon 72 polymorphism and bladder cancer in all comparisons. Conclusions: Despite the limitations, the results of the present meta-analysis suggest that, in the P53 codon 72, Pro/Pro type and dominant mode might increase the susceptibility to bladder cancer in Asians; and there are no association between genotype distribution and the stage of bladder cancer.
Keywords
P53 codon 72; bladder carcinoma; meta-analysis; polymorphism; susceptibility;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Biro E, Kalina I, Salagovic J, et al (2000). p53 single nucleotide polymorphisms and bladder cancer. Neoplasma, 47, 303-6.
2 Bryan RT, Hussain SA, James ND, et al (2005). Molecular pathways in bladder cancer: part 2. BJU Int, 95, 491-6.   DOI
3 Chang CC, Hsieh YY, Tsai FJ, et al (2002). The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril, 77, 43-5.   DOI   ScienceOn
4 Chen WC, Tsai FJ, Wu JY, et al (2000). Distributions of p53 codon 72 polymorphism in bladder cancer--proline form is prominent in invasive tumor. Urol Res, 28, 293-6.   DOI
5 Chung CJ, Huang CJ, Pu YS, et al (2008). Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. Toxicol Appl Pharmacol, 232, 203-9.   DOI
6 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI
7 Dumont P, Leu JI, Della Pietra AC, 3rd, et al (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet, 33, 357-65.   DOI   ScienceOn
8 Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI
9 Gao LL, Huang XE, Zhang Q, et al (2011). 14.A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
10 Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pacific J Cancer Prev, (in press).
11 Herr HW, Sogani PC (2001). Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol, 166, 1296-9.   DOI   ScienceOn
12 Horikawa Y, Nadaoka J, Saito M, et al (2008). Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep, 20, 49-55.
13 Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a Phase II trial. Asian Pacific J Cancer Prev, 12, 2797-800.
14 Klug SJ, Ressing M, Koenig J, et al (2009). TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol, 10, 772-84.   DOI
15 Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.   DOI
16 Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 11, 1059-62.
17 Kaufman DS, Shipley WU, Feldman AS (2009). Bladder cancer. Lancet, 374, 239-49.   DOI
18 Kuroda Y, Tsukino H, Nakao H, et al (2003). p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett, 189, 77-83.   DOI
19 Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell, 88, 323-31.   DOI   ScienceOn
20 Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of $OxyContin^{(R)}$ administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
21 Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pacific J Cancer Prev, 12, 487-90.
22 Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pacific J Cancer Prev, 13, 301-4.   DOI
23 Lin HY, Yang MC, Huang CH, et al (2011) Polymorphisms of TP53 are markers of bladder cancer vulnerability and prognosis. Urol Oncol. 2011 Dec 16.
24 Meek DW (2004). The p53 response to DNA damage. DNA Repair (Amst), 3, 1049-56.   DOI   ScienceOn
25 Li Y, Yan PW, Huang XE, et al (2011). MDR1 Gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 12, 2405-9.
26 Mabrouk I, Baccouche S, El-Abed R, et al (2003). No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci, 1010, 764-70.   DOI
27 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
28 Pandith AA, Shah ZA, Khan NP, et al (2010). Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. Cancer Genet Cytogenet, 203, 263-8.   DOI   ScienceOn
29 Sager R (1989). Tumor suppressor genes: the puzzle and the promise. Science, 246, 1406-12.   DOI
30 Santos LE, Guilhen AC, de Andrade RA, et al (2011). The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer. Urol Oncol, 29, 291-4.   DOI
31 Soulitzis N, Sourvinos G, Dokianakis DN, et al (2002). p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett, 179, 175-83.   DOI   ScienceOn
32 Srivastava P, Jaiswal PK, Singh V, et al (2010). Role of p53 gene polymorphism and bladder cancer predisposition in northern India. Cancer Biomark, 8, 21-8.
33 Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
34 Toruner GA, Ucar A, Tez M, et al (2001). P53 codon 72 polymorphism in bladder cancer--no evidence of association with increased risk or invasiveness. Urol Res, 29, 393-5.   DOI
35 Williams SG, Stein JP (2004). Molecular pathways in bladder cancer. Urol Res, 32, 373-85.   DOI
36 Wu WJ, Kakehi Y, Habuchi T, et al (1995). Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res, 86, 730-6.   DOI
37 Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
38 Xu H, el-Gewely MR (2001). P53-responsive genes and the potential for cancer diagnostics and therapeutics development. Biotechnol Annu Rev, 7, 131-64.   DOI
39 Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of $Endostar^{(R)}$ combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
40 Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
41 Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinumbased chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
42 Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a metaanalysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
43 Ye Y, Yang H, Grossman HB, et al (2008). Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer, 112, 2467-74.   DOI
44 Yu DS, Huang XE, Zhou JN, et al (2012). A Comparative Study on the Value of Anal Preserving Surgery for Aged People with Low Rectal Carcinoma in Jiangsu, China. Asian Pacific J Cancer Prev, (in press).
45 Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
46 Zhang R, Chen W, Zhang W, et al (2011). Genetic polymorphisms of p53 codon 72 and bladder cancer susceptibility: a hospitalbased case-control study. Genet Test Mol Biomarkers, 15, 337-41.   DOI
47 Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II study on voriconazole in treating Chinese patients with malignant hematological disorder and invasive aspergillosis. Asian Pacific J Cancer Prev, (in press).